Matrix metalloproteinase expression after human cardioembolic stroke: Temporal profile and relation to neurological impairment

Stroke

Volumn 32, Issue 8, 2001, Pages 1759-1766

  Montaner, Joan ^a   Alvarez Sabín, José ^a   Molina, Carlos ^a   Anglés, Ana ^a   Abilleira, Sonia ^a   Arenillas, Juan ^a   González, Miguel Angel ^a   Monasterio, Jasone ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cerebral ischemia; Matrix metalloproteinases; Stroke, cardioembolic

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; PRIORITY JOURNAL; STROKE;

EID: 0034893137     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.32.8.1759     Document Type: Article

References (28)

1. Metalloproteinases and their inhibitors in matrix remodeling
2. Matrix metalloproteinases in cerebrovascular disease
3. Matrix metalloproteinases: A minireview
4. Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: A possible role in blood brain-barrier dysfunction
5. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain
6. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia
7. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: Inhibition of matrix metalloproteinase-9 reduces infarct size
8. Role for matrix metalloproteinase 9 after focal cerebral ischemia: Effects of gene knockout and enzyme inhibition with BB-94
9. Classification of subtype of acute ischemic stroke: Definitions for use in a multicenter clinical trial
10. Urgent therapy for stroke, part I: Pilot study of tissue plasminogen activator administered within 90 minutes
11. Urgent therapy for stroke, part II: Pilot study of tissue plasminogen activator administered within 91-180 minutes from onset
12. Local intra-arterial thrombolysis in acute ischemic stroke
13. Multivariable analysis of predictive factors related to outcome at 6 months after intra-arterial thrombolysis for acute ischemic stroke
14. Progression in acute stroke: Value of the initial NIH Stroke Scale score on patient stratification in future trials
15. Interrater agreement in computed tomography infarct measurement
16. Anatomy and freehand examination techniques
17. Spontaneous middle cerebral artery reperfusion in acute ischemic stroke: A follow-up study with transcranial Doppler
18. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat
19. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion
20. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes
21. Localization of metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion
22. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke
23. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia
24. Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons
25. Human neutrophil gelatinase: A marker for circulating blood neutrophils: Purification and quantification by enzyme linked immunosorbent assay
26. Collagenolytic metalloenzymes of the human neutrophil
27. Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat)
28. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke